Navigation Links
Control of disease activity and biologic treatment increase life expectency in RA patients
Date:6/7/2012

Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).

Results of the German study of 8,908 patients demonstrated that the mortality rate decreased from 20.6 in those treated with non-biologic DMARDS to 10.6 in those exposed to anti-tumour necrosis factor (anti-TNFs) drugs, and likewise to 12.7 for those treated with rituximab.

Further analyses showed that men and women with RA had a shortened life expectancy of 2.2 years compared to the general population. Patients with a mean DAS28* below 4.1 had normal life expectancies whereas of patients with a mean DAS28 score of >4.1 women died 5.6 years earlier than age and sex matched subjects from the general population, whilst males died 4.8 years earlier.

"It is well-known that patients with RA have lower life expectancies than the general population," said Dr. Joachim Listing, German Rheumatism Research Centre Berlin, Germany and lead study author. "Our study demonstrates the positive impact that biologic treatment can have on patient's life expectancy.

According to the researchers, a significant association between disease activity and mortality risk was observed by multivariate Cox regression within the patient sample. Cox proportional hazard regression was applied to investigate the influence of the time varying DAS28 scores, functional capacity and treatments on mortality risk after adjustment for age, sex, eight co-morbid conditions and smoking. The primary analysis was based on a risk window approach assuming the patient was exposed to biologic DMARD treatment up to six months (12 months for rituximab) after the last dose. Mean observation time was 3.5 years.

Results of a separate study show that early remission is associated to better overall survival.

Results of a large observational study presented at EULAR show early and sustained remission are associated with a decreased all-cause mortality in patients in inflammatory polyarthritis. The analyses from the Norforlk arthritis register, a large population-based inception cohort of inflammatory polyarthritis established in 1990, showed that achieving remission at least once within the first three years of follow-up was associated with improved survival (adjusted HR=0.75 (0.59, 0.95), 95% CI). Number of times in remission was also associated with decreased all-cause mortality. Patients who were in remission for one year after their first assessment had the greatest reduction in mortality risk compared to patients who didn't achieve remission within the first three years (adjusted HR=0.66 (0.47, 0.92)), while patients who achieved remission at year two or three showed a progressive loss of the beneficial effect of achieving remission. This indicates that achieving remission at an early stage in the disease process is essential to improving outcome for patients with polyarthritis.

Abstract Number: OP0047, OP0126


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
2. Private Sector, President's Malaria Initiative Join Forces to Strengthen Angolas Capacity to Control Mosquitoes
3. FDA Tightens Controls on Anemia Drugs
4. High-fat ketogenic diet to control seizures is safe over long term
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Flightless mosquitoes developed to help control dengue fever
7. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
8. Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership
9. Hypnosis can help control pain among women with metastatic breast cancer, UB Researcher finds
10. AGH Study Shows High Rates of Poorly Controlled Asthma Among Inner-City Pittsburgh Children
11. Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology: